TSX runs higher on rate cut expectations
HOUSTON - Plus Therapeutics, Inc. (NASDAQ:PSTV) has regained compliance with Nasdaq’s listing requirements, according to a letter received from the exchange on August 22, 2025. The company, currently valued at $48.24 million, has seen its stock price decline 57.82% year-to-date to $0.48.
The clinical-stage pharmaceutical company, which develops targeted radiotherapeutics for central nervous system cancers, now meets two alternative criteria under Nasdaq Listing Rule 5550(b): the Market Value of Listed Securities standard, requiring maintenance of at least $35 million in market value, and the stockholders’ equity threshold of at least $2.5 million. According to InvestingPro analysis, the company maintains a weak financial health score of 1.71, with several challenges ahead including rapid cash burn and negative gross profit margins.
As a result of this compliance, Nasdaq has extended the company’s deadline to meet the $1.00 minimum bid price requirement. Plus Therapeutics now has until November 12, 2025, to address this deficiency, rather than the previously announced September 8, 2025 deadline. Investors can access detailed analysis and 11 additional key insights about PSTV through InvestingPro’s comprehensive research reports.
The company remains under a one-year monitoring period through August 22, 2026, specifically for the stockholders’ equity standard. If Plus Therapeutics fails to maintain compliance with this standard during the monitoring period and does not meet alternative standards, Nasdaq would issue a delisting determination.
Plus Therapeutics focuses on developing radiotherapeutics for difficult-to-treat cancers, with lead programs targeting leptomeningeal metastases and recurrent glioblastoma. The company has established strategic partnerships to support the development, manufacturing, and potential future commercialization of its products.
This information is based on a press release statement issued by Plus Therapeutics.
In other recent news, Plus Therapeutics, Inc. announced it has regained compliance with Nasdaq’s equity and market value standards. The company confirmed it now meets the Market Value of Listed Securities standard, requiring a market value of at least $35 million, and the stockholders’ equity threshold of at least $2.5 million. Plus Therapeutics reported a stockholders’ equity of $3 million as of June 30, 2025, which satisfies Nasdaq’s minimum requirement to maintain its listing. Additionally, the company received an extension to meet the Nasdaq minimum bid price rule by November 12, 2025. In other developments, Plus Therapeutics shared positive results from a retrospective analysis of its CNSide Cerebrospinal Fluid Assay Platform at a recent conference. The study found that tumor cells were detected in 67% of patients using this platform. Looking ahead, the company plans to launch its CNSide diagnostic platform commercially in Texas in August 2025, targeting several National Cancer Institute-Designated Cancer Centers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.